When the Notified Body says ‘six months minimum’
You submit your clinical evaluation report. The Notified Body acknowledges receipt. Then comes the timeline: ‘Initial assessment will begin in six months.’ Your project manager panics. Your stakeholders ask if this is normal. It is.
In This Article
The constraint is real. It is structural. And it affects every clinical evaluation timeline in ways that most manufacturers still underestimate.
This is not about your file being deprioritized. This is about capacity scarcity across the entire EU conformity assessment system. Understanding what drives these delays changes how you plan, how you prepare, and when you submit.
The Capacity Reality Behind the Numbers
Notified Bodies operate under MDR Article 42, which sets out strict designation criteria. These include requirements for competent personnel, independence, and sufficient resources to handle the volume and complexity of assessments.
What the regulation does not guarantee is enough designated bodies to meet market demand.
Post-MDR, the number of designated Notified Bodies dropped. The complexity of assessments increased. The volume of files requiring review surged as legacy devices transitioned and new manufacturers entered the market.
The result is a bottleneck. Not at the level of individual files, but at the level of system capacity.
Notified Body capacity is not evenly distributed. High-risk devices, novel technologies, and files requiring clinical investigations receive prioritization. Class IIa and IIb devices with equivalence claims often face the longest queues.
When you hear ‘six months,’ that is not the review time. That is the waiting time before your file enters active assessment. The actual review adds months on top of that.
What Drives the Delay
Three factors dominate capacity constraints at Notified Bodies.
First, the availability of qualified clinical assessors. MDR requires that clinical evaluation reports are reviewed by personnel with specific medical and clinical expertise. These individuals are limited in number. They cannot scale quickly. Training a new assessor to MDR standards takes years, not months.
Second, the depth of review required under MDR. Pre-MDR, many assessments were lighter. Post-MDR, every clinical evaluation must demonstrate compliance with Annex XIV Part A, equivalence must be robustly justified, PMCF must be credible, and clinical data must be current.
This means longer review times per file. A file that once took two weeks now takes six. Multiply that across hundreds of submissions.
Third, the concentration of submissions around deadlines. When manufacturers rush to meet transition deadlines or renewal dates, submissions cluster. Notified Bodies receive waves of files simultaneously. The queue lengthens.
Manufacturers assume that submitting early guarantees early review. In practice, early submission without full readiness leads to rejection or suspension, which resets the timeline and wastes the queue position.
The Notified Body does not benefit from delays. They operate under contractual and regulatory pressure to deliver. But they cannot compromise the rigor of assessment to meet manufacturer timelines.
What This Means for Your Clinical Evaluation Timeline
The impact on your project is direct.
If you plan a product launch assuming a three-month review, and the actual timeline is nine months waiting plus four months review, you miss the market window. Investors lose confidence. Competitors gain ground.
But the effect goes deeper than delay.
When Notified Bodies operate under capacity pressure, they become less tolerant of incomplete submissions. A file that arrives with gaps, unclear equivalence justification, or weak PMCF planning gets rejected faster. The assessor does not have time to guide you through revisions.
This creates a paradox. The tighter the capacity, the higher the quality bar at submission. You cannot afford to submit a draft and iterate. You must submit ready.
A rejected submission does not return to the front of the queue. It goes to the back. The cost of a poorly prepared file is not measured in weeks, but in quarters.
For clinical evaluation, this means your CER must be complete at first submission. The literature search must be current. The equivalence demonstration must be unambiguous. The PMCF plan must be credible and specific.
There is no room for ‘we will clarify that in the next revision.’
Strategic Adjustments Manufacturers Must Make
Understanding capacity constraints changes how you approach timelines.
First, build longer lead times into your project plan. If you historically allowed four months from submission to approval, plan for twelve. This is not pessimism. It is realism.
Second, engage with your Notified Body earlier. Not to bypass the queue, but to understand their current processing times, their expectations for your device class, and any known bottlenecks in their assessment process.
Some Notified Bodies provide pre-submission consultations. Use them. A thirty-minute discussion about your equivalence strategy or PMCF scope can prevent a three-month delay later.
Third, prioritize submission readiness over submission speed. Do not submit because the calendar says it is time. Submit when the file is truly complete.
This requires honest internal assessment. Can your clinical evaluation report withstand a critical review by an experienced assessor? Does your SOTA reflect the current literature, or is it six months outdated? Is your equivalence claim backed by data, or by assumptions?
Manufacturers treat submission as a deadline instead of a quality gate. The pressure to ‘get it in’ overrides the discipline to ‘get it right.’ The result is a submission that gets parked in the rejection pile while better-prepared files move forward.
Fourth, consider the strategic value of early preparation for future submissions. If your next-generation device will require a new clinical evaluation in eighteen months, start the literature review now. Build the SOTA progressively. Do not compress the entire clinical evaluation into the final quarter before submission.
The Files That Move Faster
Not all submissions experience the same delay.
Notified Bodies prioritize based on risk, complexity, and regulatory urgency. A Class III implantable device receives attention before a Class IIa diagnostic. A file supporting a significant design change moves ahead of a routine renewal.
Files that are complete, well-structured, and clearly compliant also process faster. When an assessor opens a CER and immediately finds a current literature search, a clear clinical benefit-risk conclusion, and a coherent PMCF plan, the review is smoother.
Conversely, files that require repeated clarification requests extend the timeline. Each question sent to the manufacturer adds two to four weeks. Three rounds of clarifications can add three months.
The quality of your submission directly influences the speed of your assessment, independent of the queue.
Notified Bodies do not reward speed. They reward completeness. A file submitted two months later but fully prepared will often achieve certification before a file submitted early but incomplete.
What You Can Control
You cannot change the capacity constraints at Notified Bodies. You cannot force them to hire more assessors or process files faster.
But you can control your preparation.
Start your clinical evaluation earlier. Allocate sufficient resources to clinical data analysis. Engage clinical experts during development, not just before submission. Treat the CER as a living document that evolves with your project, not a final deliverable produced under deadline pressure.
Plan your PMCF activities before you need them. If your Notified Body will ask for PMCF data at renewal, start collecting now. Do not wait until the renewal submission is due.
Document your clinical rationale as you make design decisions. Capture the clinical evidence supporting each change. This documentation becomes the foundation of your CER and shortens preparation time later.
Most importantly, align your internal stakeholders on realistic timelines. The belief that ‘we can submit in three months and launch in six’ creates pressure that leads to rushed submissions, rejections, and extended delays.
Replace optimism with informed planning.
The Long View
Notified Body capacity constraints are not temporary. They reflect the structural reality of MDR implementation.
As manufacturers adapt, as Notified Bodies optimize their processes, and as more bodies achieve designation, the pressure may ease slightly. But it will not disappear.
The system requires rigor. Rigor requires time. Time requires planning.
Manufacturers who build this understanding into their development process from the start will navigate the system more effectively than those who treat it as an obstacle to overcome at the end.
Your clinical evaluation timeline is not just about your file. It is about the entire regulatory ecosystem you operate within. Adjust accordingly.
Next in this series, we examine what happens during the Notified Body review itself—the questions they ask, the deficiencies they flag, and how to respond without extending the timeline further.
Peace,
Hatem
Clinical Evaluation Expert for Medical Devices
Follow me for more insights and practical advice.
– MDR 2017/745 Article 42 (Notified Body designation requirements)
– MDR 2017/745 Annex XIV Part A (Clinical evaluation requirements)
Frequently Asked Questions
What is a Clinical Evaluation Report (CER)?
A CER is a mandatory document under MDR 2017/745 that demonstrates the safety and performance of a medical device through systematic analysis of clinical data. It must be updated throughout the device lifecycle based on PMCF findings.
How often should the CER be updated?
The CER should be updated whenever significant new clinical data becomes available, after PMCF activities, when there are changes to the device or intended purpose, and at minimum during annual reviews as part of post-market surveillance.
What causes CER rejection by Notified Bodies?
Common reasons include inadequate equivalence demonstration, insufficient clinical data for claims, poorly structured SOTA analysis, missing gap analysis, and lack of clear benefit-risk determination. Structure and logical flow are as important as the data itself.
Which MDCG guidance documents are most relevant for clinical evaluation?
Key documents include MDCG 2020-5 (Equivalence), MDCG 2020-6 (Sufficient Clinical Evidence), MDCG 2020-13 (CEAR Template), MDCG 2020-7 (PMCF Plan), and MDCG 2020-8 (PMCF Evaluation Report). MDR Article 42
Need Expert Help with Your Clinical Evaluation?
Get personalized guidance on MDR compliance, CER writing, and Notified Body preparation.
✌
Peace, Hatem
Your Clinical Evaluation Partner
Follow me for more insights and practical advice.
Extended NB review timelines increase project costs. Plan your budget with our detailed CE marking costs for medical devices.
Deepen Your Knowledge
Read Complete Guide to Clinical Evaluation under EU MDR for a comprehensive overview of clinical evaluation under EU MDR 2017/745.
